Recent evidence indicates that, beyond TFR1 and DMT1, lipocalin-2 (LCN2, also called neutrophil gelatinase-associated lipocalin or NGAL) provides an alternative iron-delivery pathway that is exploited by multiple tumor types. The gene discussed is LCN2; the disease is neoplasm.